The mTOR inhibitor, rapamycin, targeted the mTOR–HIF-1α axis and induced colon cancer cells to become sensitive to irinotecan, both in vitro and in vivo study using a xenografted metastasis model of human colorectal cancer. Here, MTOR is linked to colonic neoplasm.